- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05701241
Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients (SAUNA)
July 10, 2023 updated by: University Hospital, Antwerp
Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients - The SAUNA Trial
The SAUNA trial is a multi-national, multi-centre, open-label, randomised, controlled, pragmatic clinical trial in patients with advanced, non-functional gastroenteropancreatic (GEP) neuroendocrine tumours (NET) with progressive disease on first-line therapy with somatostatine analogues (SSA).
Eligible patients will be divided into two substudies according to the second-line therapy of choice (peptide receptor radionuclide therapy (PRRT) or targeted therapy, at the discretion of the local investigator).
Patients within each substudy will be randomised 1:1 between continuation or withdrawal from SSA at the start of second-line systemic therapy.
Stratification will occur according to study site and according to the Ki67 value (below 10% (grade 1 and low grade 2) and equal to or above 10% (high grade 2)).
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
270
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Marc U Peeters, MD
- Phone Number: 4366 03821
- Email: sauna@uza.be
Study Contact Backup
- Name: Timon Vandamme, MD
- Email: timon.vandamme@uza.be
Study Locations
-
-
-
Antwerp, Belgium
- Not yet recruiting
- GZA
-
Contact:
- Isabelle Maurissen
-
Antwerpen, Belgium
- Not yet recruiting
- AZ Monica
-
Contact:
- Timon Vandamme
-
Antwerpen, Belgium
- Not yet recruiting
- Ziekenhuis Netwerk Antwerpen
-
Contact:
- Frank Van Fraeyenhove
-
Brussel, Belgium
- Not yet recruiting
- Cliniques Universitaires Saint-Luc
-
Contact:
- Ivan Borbath
-
Brussels, Belgium
- Not yet recruiting
- H.U.B.
-
Contact:
- Ioannis Karfis
-
Edegem, Belgium
- Recruiting
- Antwerp University Hospital
-
Contact:
- Timon Vandamme
- Email: sauna@uza.be
-
Liège, Belgium
- Not yet recruiting
- Centre Hospitalier Universitaire Sart Tilman
-
Contact:
- Laurence Lousberg
-
Malle, Belgium
- Not yet recruiting
- AZ Voorkempen
-
Contact:
- Wim Demey
-
-
Antwerp
-
Brasschaat, Antwerp, Belgium
- Not yet recruiting
- AZ Klina
-
Contact:
- Wim Demey
-
Rumst, Antwerp, Belgium
- Not yet recruiting
- AZ Rivierenland
-
Contact:
- Marijke Ulenaers
-
-
East Flanders
-
Ghent, East Flanders, Belgium
- Not yet recruiting
- Ghent University Hospital
-
Contact:
- Karen Geboes
-
-
East-Flanders
-
Sint-Niklaas, East-Flanders, Belgium
- Not yet recruiting
- VITAZ
-
Contact:
- Willem Lybaert
-
-
Flemish Brabant
-
Leuven, Flemish Brabant, Belgium
- Not yet recruiting
- University Hospital Leuven
-
Contact:
- Chris Verslype
-
-
Hainaut
-
Charleroi, Hainaut, Belgium
- Not yet recruiting
- Grand Hopital de Charleroi
-
Contact:
- Isabelle Sinapi
-
-
-
-
-
Groningen, Netherlands
- Not yet recruiting
- UMC Groningen
-
Contact:
- Annemiek Walenkamp
-
Rotterdam, Netherlands
- Not yet recruiting
- Erasmus MC
-
Contact:
- Wouter de Herder
-
-
Gelderland
-
Arnhem, Gelderland, Netherlands
- Not yet recruiting
- Rijstate
-
Contact:
- Theo Van Voorthuizen
-
-
Limburg
-
Maastricht, Limburg, Netherlands
- Not yet recruiting
- Maastricht UMC+
-
Contact:
- Loes Latten-Jansen
-
-
North Brabant
-
Eindhoven, North Brabant, Netherlands
- Not yet recruiting
- Máxima Medisch Centrum
-
Contact:
- Wouter Dercksen
-
-
North Holland
-
Amsterdam, North Holland, Netherlands
- Not yet recruiting
- Amsterdam UMC
-
Contact:
- Heinz-Josef Klumpen
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Age ≥18 years
- Written informed consent prior to any study-related procedures
- Eastern Cooperative Oncology Group (ECOG) performance status ≤2,
- Histologically-proven diagnosis of locally advanced or metastatic, non-functional, well-differentiated World Health Organisation 2019 grade 1-2 GEP NET
- Documented radiological disease progression on first-line SSA treatment
- For targeted therapy substudy: indication to start with either sunitinib or everolimus as second-line therapy, according to local investigator
- For PRRT substudy: indication to start with PRRT with Lutetium (177Lu) oxodotreotide as second-line therapy, according to local investigator
Exclusion Criteria:
- Indication for chemotherapy treatment of GEP NET in second-line
- Presence of poorly differentiated grade 3 neuroendocrine carcinoma (NEC), well-differentiated grade 3 NET or rapidly progressive NET
- Prior treatment with everolimus, sunitinib or PRRT
- Contra-indication, proven allergy or other indication than functional NET for the use of a SSA
- Patient showing progressive disease while being on a lower than the registered dose
- Functional NET, defined as the presence of clinical and biochemical evidence of a hormonal NET-related syndrome
- Patient undergoing palliative, systemic oncological treatment for other malignancy than GEP NET
- Concurrent anti-cancer treatment in another investigational trial
- Any abnormal findings at baseline, clinical finding, including psychiatric and behavioural problems, or any other medical condition(s) or laboratory findings that, in the opinion of the investigator, might jeopardize the patient's safety or decrease the chance of obtaining satisfactory data needed to achieve the objective(s) of the study
- Pregnant or lactating patient at screening or if the patient wishes to get pregnant during treatment phase of the trial
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: somatostatin analogs continuation
Somatostatin analog (octreotide long-acting release (LAR) 30 mg or lanreotide 120 mg) will be given every four weeks for a duration of 18 months.
|
Somatostatin analog treatment every 4 weeks
Other Names:
|
No Intervention: somatostatin analogs withdrawal
Somatostatin analog treatment (octreotide LAR 30 mg or lanreotide 120 mg) will be withdrawn for a duration of 18 months.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
the difference in progression-free survival (PFS) in patients continuing or stopping second-line therapy with SSAs, as assessed by the blinded local investigator on cross-sectional imaging, according to RECIST 1.1 criteria per substudy
Time Frame: 18 months after start second-line treatment
|
PFS
|
18 months after start second-line treatment
|
The difference in time to deterioration (TTD) in patients continuing or stopping second-line therapy with SSAs per substudy
Time Frame: 18 months after start second-line treatment
|
TTD
|
18 months after start second-line treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
progression-free survival rate according to RECIST 1.1
Time Frame: 18 months after start second-line treatment
|
PFS rate
|
18 months after start second-line treatment
|
The difference in a pooled progression-free survival of both substudies
Time Frame: 18 months after start second-line treatment
|
PFS
|
18 months after start second-line treatment
|
The difference in a pooled time to deterioration of both substudies
Time Frame: 18 months after start second-line treatment
|
TTD
|
18 months after start second-line treatment
|
Overall survival (OS) per substudy and pooled over both substudies
Time Frame: Time until death; assessed up to 5 years after treatment phase
|
OS
|
Time until death; assessed up to 5 years after treatment phase
|
Overall survival pooled over both substudies
Time Frame: Time until death; assessed up to 5 years after treatment phase
|
OS
|
Time until death; assessed up to 5 years after treatment phase
|
Response rates (RR) per substudy
Time Frame: 18 months after start second-line treatment
|
RR
|
18 months after start second-line treatment
|
Response rates over both substudies
Time Frame: 18 months after start second-line treatment
|
RR
|
18 months after start second-line treatment
|
Quality of life (QoL) measurement with questionnaire
Time Frame: End of study (6.5 years after start second-line treatment)
|
QoL measurement with 30-item Quality of Life Questionnaire (QLQ-C30)
|
End of study (6.5 years after start second-line treatment)
|
Quality of life (QoL) measurement with questionnaire
Time Frame: End of study (6.5 years after start second-line treatment)
|
QoL measurement with 21-item QoL questionnaire in the gut, pancreas and liver neuroendocrine tumours (QLQ-GINET21)
|
End of study (6.5 years after start second-line treatment)
|
Quality of life (QoL) measurement with questionnaire
Time Frame: End of study (6.5 years after start second-line treatment)
|
QoL measurement with EuroQol-5 Dimensions-5 Level questionnaire
|
End of study (6.5 years after start second-line treatment)
|
Cost-effectiveness
Time Frame: End of study (6.5 years after start second-line treatment)
|
Health technology assessment (HTA) analysis
|
End of study (6.5 years after start second-line treatment)
|
Drug safety
Time Frame: 18 months after start second-line treatment
|
Safety will be reported in terms of incidence and severity of (serious) adverse events
|
18 months after start second-line treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Marc Peeters, MD, University Hospital, Antwerp
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 28, 2023
Primary Completion (Estimated)
April 1, 2029
Study Completion (Estimated)
April 1, 2034
Study Registration Dates
First Submitted
January 5, 2023
First Submitted That Met QC Criteria
January 17, 2023
First Posted (Actual)
January 27, 2023
Study Record Updates
Last Update Posted (Actual)
July 12, 2023
Last Update Submitted That Met QC Criteria
July 10, 2023
Last Verified
January 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Neuroendocrine Tumors
- Physiological Effects of Drugs
- Antineoplastic Agents
- Gastrointestinal Agents
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Octreotide
- Lanreotide
- Somatostatin
Other Study ID Numbers
- EDGE 002337
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastroenteropancreatic Neuroendocrine Tumor
-
Grupo Espanol de Tumores NeuroendocrinosActive, not recruitingNeuroendocrine Tumors | Neuroendocrine Neoplasm | Gastroenteropancreatic Neuroendocrine TumorSpain
-
Amr Mohamed MDNovatek PharmaceuticalsRecruitingNeuroendocrine Carcinoma | Gastroenteropancreatic Neuroendocrine Tumor | Gastroenteropancreatic Neuroendocrine Neoplasm | Mixed Neuroendocrine-Non Neuroendocrine NeoplasmUnited States
-
Jiangsu HengRui Medicine Co., Ltd.RecruitingAdvanced Gastroenteropancreatic Neuroendocrine TumorChina
-
Jiangsu HengRui Medicine Co., Ltd.Not yet recruitingAdvanced Gastroenteropancreatic Neuroendocrine Tumor
-
University of IowaPatient-Centered Outcomes Research Institute; Medical University of South Carolina and other collaboratorsEnrolling by invitationNeuroendocrine Tumors | Neuroendocrine Carcinoma | Lung Neuroendocrine Neoplasm | Gastroenteropancreatic Neuroendocrine TumorUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteCompletedLung Neuroendocrine Neoplasm | Gastroenteropancreatic Neuroendocrine TumorUnited States
-
RayzeBio, Inc.RecruitingNeuroendocrine Tumors | Carcinoid Tumor | Gastroenteropancreatic Neuroendocrine Tumor | Carcinoid | GEP-NET | Gastroenteropancreatic Neuroendocrine Tumor Disease | Pancreatic NETUnited States, Canada, Belgium, Netherlands, France, Spain, Brazil
-
Wren Laboratories LLCActive, not recruitingNeuroendocrine Tumor | GastroenteropancreaticItaly
-
IpsenCompletedGastro-Enteropancreatic Neuroendocrine TumorUnited States, Austria, Denmark
-
National Health Research Institutes, TaiwanNational Taiwan University Hospital; Mackay Memorial Hospital; China Medical... and other collaboratorsRecruitingNeuroendocrine Tumors,GastroenteropancreaticTaiwan
Clinical Trials on Somatostatin analog
-
Medical University of ViennaNot yet recruitingPancreatic Neuroendocrine Tumors in MEN1
-
University of AarhusUnknownNeuroendocrine Tumors (NET) Health Related Qualito of Life (HRQoL)Denmark
-
University of Roma La SapienzaRecruitingNeuroendocrine Tumors | Neuroendocrine Carcinoma | Neuroendocrine Neoplasm | Neuroendocrine Tumor Grade 2 | Neuroendocrine Tumor Grade 1Italy
-
Mayo ClinicEnrolling by invitationPancreatic DiseasesUnited States
-
National Cancer Institute, NaplesCompletedNeuroendocrine TumorsItaly
-
National Cancer Institute, NaplesFederico II University; University of Campania "Luigi Vanvitelli"Terminated
-
ItalfarmacoCompletedAcromegalyFrance, Hungary, Netherlands, Serbia, Czech Republic, Italy, Spain, Poland, Romania
-
University of AarhusAarhus University Hospital; Aarhus University Hospital Skejby; The Research Council...CompletedCo-treatment With Pegvisomant and a Somatostatin Analogue (SA) in SA-responsive Acromegalic PatientsInsulin Resistance | Acromegaly | Impaired Glucose ToleranceDenmark
-
University Hospital, Basel, SwitzerlandCompleted
-
Dana-Farber Cancer InstituteEli Lilly and CompanyActive, not recruitingCarcinoid TumorsUnited States